Tissue Repair & Regenerative

TB-500 (Thymosin Beta-4 / Ac-SDKP)

For Research Use Only. Not for Human or Veterinary Use.

Overview

TB-500 refers to synthetic material based on Thymosin Beta-4 (Tβ4), a 43-amino-acid actin-sequestering protein present in essentially all mammalian tissues, and specifically to its acetylated active fragment Ac-SDKP (Acetyl-Ser-Asp-Lys-Pro). Tβ4 and its fragment are studied in preclinical regenerative research for wound healing, angiogenesis, cell migration, anti-inflammatory and cytoprotective effects. It is a research compound.

Chemical Profile

PropertyValue
CAS number77591-33-4 (Ac-SDKP fragment)
ClassActin-sequestering peptide / Thymosin Beta-4 fragment
Active fragmentAc-Ser-Asp-Lys-Pro (Ac-SDKP)
Molecular formula (fragment)C₂₀H₃₂N₄O₉
Molecular weight (fragment)500.52 g/mol
Full Tβ4 (43 aa)≈ 4963 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
TB-500 at a glance
Class
Actin-sequestering peptide (Tβ4 / Ac-SDKP)
Origin
Thymosin Beta-4, endogenous 43-aa protein
Research status
Extensive preclinical; limited clinical
Study routes
SC, IM, IV, topical
Half-life
≈ 2–6 h (fragment)
Key feature
Angiogenic and wound-healing peptide

Mechanism of Action

The defining biochemistry of Thymosin Beta-4 is that it binds monomeric (G-)actin in a 1:1 complex, acting as the cell’s main actin buffer and so regulating the assembly of the cytoskeleton that drives cell movement. On top of this actin role, Tβ4 and Ac-SDKP are studied for angiogenic, anti-inflammatory and cytoprotective signalling.

ComponentResearch description
Primary targetG-actin — sequesters actin monomers (1:1)
AngiogenesisAssociated with VEGF, MMP-2/9 and endothelial-cell migration
Cell migrationPromotes chemotaxis of endothelial cells, keratinocytes and fibroblasts
Anti-apoptotic tonePI3K/Akt activation; Bcl-2 up, Bax down in models
Anti-inflammatory toneReduced NF-κB activation; lower TNF-α and IL-1β
Cardioprotective signallingAkt/eNOS activation in cardiomyocytes

Tissue-specific effects reported in the literature (research context, not therapeutic claims):

TissueStudied mechanismReported direction
SkinKeratinocyte migration, granulation tissueAccelerated wound closure in models
Cardiac muscleMyocyte survival, reduced fibrosisImproved post-injury function in models
CorneaEpithelial migration, reduced inflammationEnhanced corneal healing in models
Skeletal muscleSatellite-cell activation, reduced fibrosisImproved regeneration in models
Nervous systemNeurite outgrowth, oligodendrocyte differentiationNeuroprotective effects in models

Pharmacology

ParameterValue
Half-life (t½)≈ 2–6 h (Ac-SDKP); ~12–24 h (full Tβ4)
Bioavailability (SC)≈ 30–50% (estimated)
Bioavailability (oral)Poor (proteolytic degradation in the GI tract)
Protein bindingModerate (actin binding provides a tissue reservoir)
MetabolismProteolytic degradation by aminopeptidases
Route of administrationSC, IM, IV, topical (research settings)
EliminationRenal (peptide fragments)

Research Evidence

Thymosin Beta-4 has a substantial preclinical literature and some early-stage clinical work. Representative models and their focus are named below; specific numerical outcomes are not restated here as claims.

ModelResearch focusReference
Mouse skin-wound modelsAngiogenesis and wound healingMalinda KM, et al. (1999)
Rat corneal-epithelial woundCorneal healing and inflammationSosne G, et al. (2005)
Murine myocardial injuryCardiomyocyte survival and functionBock-Marquette I, et al. (2004)
Rodent CNS-injury modelsNeuroprotection and repairTβ4 preclinical literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Accelerated wound closure and angiogenesismouse wound modelMalinda KM et al., 1999
Improved post-injury cardiac functionmurine myocardial infarctionBock-Marquette I et al., 2004
Enhanced corneal epithelial healingrat corneaSosne G et al., 2005

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 1–5 mg per injection, 1–2× per week, in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Reconstitution volume1–2 mL per vial
Final concentration≈ 5–10 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~7 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published observations from research studies, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions; occasional transient headache
CytotoxicityNo cytotoxicity observed in cell assays
GenotoxicityNegative in standard assays
CardiovascularNo adverse cardiac effects reported in models
ImmunogenicityLow; anti-Tβ4 antibodies uncommon
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 50 mg/mL)
logP (octanol/water)≈ −3.1 (hydrophilic)
Isoelectric point (pI)≈ 4.8 (Ac-SDKP fragment)
pH (reconstituted)5.5–6.5
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

The Ac-SDKP fragment is produced by Fmoc solid-phase peptide synthesis with N-terminal acetylation; full-length Thymosin Beta-4 is a longer 43-residue synthesis. Both are purified by preparative HPLC to research grade.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide MBHA resin
CouplingHBTU / HOBt with DIPEA in DMF
N-terminal acetylationAcetic anhydride / DIPEA (for Ac-SDKP)
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Full-length Tβ4 is characterised as a longer peptide; the Ac-SDKP fragment is the active tetrapeptide.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 501 Da (Ac-SDKP fragment)
MALDI-TOFMass confirmation[M+H]⁺ ≈ 501 Da (Ac-SDKP fragment)
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 501 Da (Ac-SDKP fragment)). Full-length Tβ4 is characterised as a longer peptide; the Ac-SDKP fragment is the active tetrapeptide.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Full-length Tβ4 is characterised as a longer peptide; the Ac-SDKP fragment is the active tetrapeptide.

Selected References

  • Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
  • Sosne G, et al. Thymosin beta-4 promotes corneal wound healing and reduces inflammation. Experimental Eye Research, 2005.
  • Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac survival and repair. Nature, 2004.
  • Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin beta-4. (review literature).

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Ac-SDKP fragment or full-length Tβ4 available on request
  • Research samples through to bulk, with worldwide delivery

Need TB-500 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote